ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group, Nielsen, H & Thisted, R K 2022, ' Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO) : a randomised controlled trial ', The Lancet. Infectious diseases, vol. 22, no. 5, pp. 622-635 . https://doi.org/10.1016/S1473-3099(21)00751-9 ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group, Johansen, I S & Larsen, L 2022, ' Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO) : a randomised controlled trial ', The Lancet Infectious Diseases, vol. 22, no. 5, pp. 622-635 . https://doi.org/10.1016/S1473-3099(21)00751-9 The Lancet. Infectious Diseases
RECOVERY Collaborative Group & Downey, D 2022, ' Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial ', The Lancet, vol. 399, no. 10325, pp. 665-676 . https://doi.org/10.1016/S0140-6736(22)00163-5 Mumford, A D 2022, ' Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial ', Lancet, vol. 399, no. 10325, pp. 665-676 . https://doi.org/10.1016/S0140-6736(22)00163-5 Lancet (London, England) Group, RECOVERY C, Felton, T, Dark, P & Mathioudakis, A 2022, ' Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial ', Lancet (London, England), vol. 399, no. 10325, pp. 665-676 . https://doi.org/10.1016/S0140-6736(22)00163-5